Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1986 8
1987 7
1988 3
1989 1
1990 5
1991 6
1992 6
1993 12
1994 14
1995 7
1996 7
1997 8
1998 10
1999 12
2000 10
2001 6
2002 7
2003 6
2004 6
2005 9
2006 11
2007 6
2008 9
2009 10
2010 14
2011 12
2012 11
2013 9
2014 3
2015 7
2016 8
2017 9
2018 5
2019 9
2020 5
2021 8
2022 4
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Results by year

Filters applied: . Clear all
Page 1
Bispecific T cell-engager targeting oncofetal chondroitin sulfate induces complete tumor regression and protective immune memory in mice.
Skeltved N, Nordmaj MA, Berendtsen NT, Dagil R, Stormer EMR, Al-Nakouzi N, Jiang K, Aicher A, Heeschen C, Gustavsson T, Choudhary S, Gögenur I, Christensen JP, Theander TG, Daugaard M, Salanti A, Nielsen MA. Skeltved N, et al. Among authors: theander tg. J Exp Clin Cancer Res. 2023 Apr 28;42(1):106. doi: 10.1186/s13046-023-02655-8. J Exp Clin Cancer Res. 2023. PMID: 37118819 Free PMC article.
[Leishmaniasis].
Kemp M, Theander TG. Kemp M, et al. Among authors: theander tg. Ugeskr Laeger. 2000 Nov 13;162(46):6203-7. Ugeskr Laeger. 2000. PMID: 11107967 Review. Danish.
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.
Smit MJ, Sander AF, Ariaans MBPA, Fougeroux C, Heinzel C, Fendel R, Esen M, Kremsner PG, Ter Heine R, Wertheim HF, Idorn M, Paludan SR, Underwood AP, Binderup A, Ramirez S, Bukh J, Soegaard M, Erdogan SM, Gustavsson T, Clemmensen S, Theander TG, Salanti A, Hamborg M, de Jongh WA, McCall MBB, Nielsen MA, Mordmüller BG; COUGH-1 trial study group. Smit MJ, et al. Among authors: theander tg. Lancet Microbe. 2023 Mar;4(3):e140-e148. doi: 10.1016/S2666-5247(22)00337-8. Epub 2023 Jan 18. Lancet Microbe. 2023. PMID: 36681093 Free PMC article. Clinical Trial.
T-cell responses in malaria.
Hviid L, Jakobsen PH, Abu-Zeid YA, Theander TG. Hviid L, et al. Among authors: theander tg. APMIS. 1992 Feb;100(2):95-106. doi: 10.1111/j.1699-0463.1992.tb00846.x. APMIS. 1992. PMID: 1554496 Review.
Contact allergens in African countries: A review of published patch test studies.
Bonefeld NM, Menné T, Ahrensbøll-Friis U, Gadsbøll AØ, Wang CW, Theander TG, Masenga EJ, Mavura D, Ødum N, Bonefeld CM, Geisler C. Bonefeld NM, et al. Among authors: theander tg. Contact Dermatitis. 2024 Feb;90(2):103-109. doi: 10.1111/cod.14471. Epub 2023 Dec 12. Contact Dermatitis. 2024. PMID: 38086538 Review.
T-cell response in human leishmaniasis.
Kharazmi A, Kemp K, Ismail A, Gasim S, Gaafar A, Kurtzhals JA, El Hassan AM, Theander TG, Kemp M. Kharazmi A, et al. Among authors: theander tg. Immunol Lett. 1999 Jan;65(1-2):105-8. doi: 10.1016/s0165-2478(98)00132-1. Immunol Lett. 1999. PMID: 10065635 Review.
Broadly inhibitory antibodies against severe malaria virulence proteins.
Reyes RA, Raghavan SSR, Hurlburt NK, Introini V, Kana IH, Jensen RW, Martinez-Scholze E, Gestal-Mato M, Bau CB, Fernández-Quintero ML, Loeffler JR, Ferguson JA, Lee WH, Martin GM, Theander TG, Ssewanyana I, Feeney ME, Greenhouse B, Bol S, Ward AB, Bernabeu M, Pancera M, Turner L, Bunnik EM, Lavstsen T. Reyes RA, et al. Among authors: theander tg. bioRxiv [Preprint]. 2024 Jan 25:2024.01.25.577124. doi: 10.1101/2024.01.25.577124. bioRxiv. 2024. PMID: 38328068 Free PMC article. Preprint.
286 results